Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery

15 Jul 2021

Abstract excerpt

Successful outcome of immune checkpoint blockade in patients with solid cancers is in part associated with a high tumor mutational burden (TMB) and the recognition of private neoantigens by T-cells. The quality and quantity of target recognition is determined by the repertoire of 'neoepitope'-specific T-cell receptors (TCRs) in tumor-infiltrating lymphocytes (TIL), or peripheral T-cells. Interferon gamma (IFN-γ),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34335558
DOI: 10.3389/fimmu.2021.592031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Neoepitopes to Treat Solid Malignancies: ImmunosurgeryPMID 34335558Read ↗

New emerging targets in cancer immunotherapy: the role of neoantigensSemantic proximity Read ↗

Neoantigen-based cancer immunotherapySemantic proximity Read ↗

The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives.Semantic proximity Read ↗

Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and ImmunotherapySemantic proximity Read ↗

Progress in Neoantigen Targeted Cancer ImmunotherapiesSemantic proximity Read ↗

Identification and characterization of neoantigen-reactive CD8+ T cells following checkpoint blockade therapy in a pan-cancer settingSemantic proximity Read ↗

Neoantigens: The Novel Precision Cancer ImmunotherapySemantic proximity Read ↗

Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.Semantic proximity Read ↗

The double-edged sword of cancer mutations: exploiting neoepitopes for the fight against cancer.Semantic proximity Read ↗

Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display.Semantic proximity Read ↗

Discovery of prevalent, clinically actionable tumor neoepitopes via integrated biochemical and cell-based platformsSemantic proximity Read ↗

Cancer immunotherapy: broadening the scope of targetable tumours.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.